AOA Dx

AOA Dx is a women's health diagnostics company that develops blood tests for early cancer detection. Its technology pairs lipid and protein biomarker measurements with machine learning. Its products include Omira Discovery, a multi-omics discovery platform, and Omira OC, a blood test for early-stage ovarian cancer.

The company competes against single-marker diagnostics for ovarian cancer, where early detection is often delayed. Its multi-omic method integrates lipid, protein, and metabolite signatures instead of relying on one biomarker layer. Studies run with the University of Colorado Anschutz Medical Campus and the University of Manchester analyzed samples from about 1,000 symptomatic women, and the company has presented results at AACR and ASCO meetings reporting higher early-stage sensitivity than the CA-125 standard biomarker.